(Reuters) – Novo Nordisk (NYSE:NVO) has raised the outlook for its full-year sales and operating profit, the Danish drugmaker said in a statement on Friday.
Novo has raised its sales growth outlook to a range between 32% and 38% from a previous 27-33%, and has raised the outlook for growth in earnings before interest and tax (EBIT) to 40-46% from previous 31-37%.
The new sales outlook for this year 2023 primarily reflects higher expectations for profits related to sales of its Ozempic and Wegovy drugs in the United States.
